Squamous Cell Carcinoma of the Oral Cavity

Oncology
2
Pipeline Programs
3
Companies
24
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Teva
TevaIsrael - Petach Tikva
1 program
1
LIPhase 35 trials
Active Trials
NCT06365788Recruiting53Est. Dec 2028
NCT04729621Completed332Est. Jun 2023
NCT04392648Withdrawn0Est. Nov 2023
+2 more trials
C
CEL-SCIVA - Vienna
1 program
1
LIPhase 31 trial
Active Trials
NCT01265849Completed928Est. Dec 2020
M&
Merck & Co.RAHWAY, NJ
1 program
data collectionN/A1 trial
Active Trials
NCT06380686Recruiting120Est. Nov 2030

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
TevaLI
TevaLI
TevaLI
CEL-SCILI
TevaLI
TevaLI
TevaLI
TevaLI
TevaLI
TevaLI
TevaLI
TevaLI
TevaLI
TevaLI
TevaLI

Showing 15 of 24 trials with date data

Clinical Trials (24)

Total enrollment: 138,486 patients across 24 trials

NCT04729621TevaLI

A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis

Start: Mar 2021Est. completion: Jun 2023332 patients
Phase 3Completed
NCT03954444TevaLI

A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"

Start: Apr 2019Est. completion: Feb 20201,105 patients
Phase 3Completed
NCT03301649TevaLI

Clinical Endpoint Study of Ivermectin 0.5% Lotion

Start: Oct 2017Est. completion: Mar 2018905 patients
Phase 3Completed
NCT01265849CEL-SCILI

Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity

Start: Dec 2010Est. completion: Dec 2020928 patients
Phase 3Completed
NCT00685113TevaLI

A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder

Start: May 2008Est. completion: Mar 20101,104 patients
Phase 3Completed
NCT00196378TevaLI

A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy

Start: Nov 2004Est. completion: Feb 2006300 patients
Phase 3Completed
NCT06365788TevaLI

Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer

Start: Apr 2024Est. completion: Dec 202853 patients
Phase 2Recruiting
NCT02365636TevaLI

A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN)

Start: Feb 2015Est. completion: May 2017300 patients
Phase 2Completed
NCT01311713TevaLI

Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors

Start: May 2011Est. completion: Oct 201345 patients
Phase 1/2Terminated
NCT04392648TevaLI

A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Start: Jun 2020Est. completion: Nov 20230
Phase 1Withdrawn
NCT01922752TevaLI

To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors

Start: Jul 2013Est. completion: Dec 201532 patients
Phase 1Completed
NCT01345357TevaLI

Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma

Start: May 2011Est. completion: Jan 201324 patients
Phase 1Completed
NCT00829790TevaLI

Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fed Conditions

Start: Oct 2006Est. completion: Oct 200630 patients
Phase 1Completed
NCT00829764TevaLI

Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fasting Conditions

Start: Oct 2006Est. completion: Oct 200630 patients
Phase 1Completed
NCT00835172TevaLI

Glimepiride 4 mg Tablets Under Non-Fasting Conditions

Start: Mar 2003Est. completion: Mar 200332 patients
Phase 1Completed
NCT00840099TevaLI

600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions

Start: Aug 2002Est. completion: Aug 200248 patients
Phase 1Completed
NCT06380686Merck & Co.data collection

Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome

Start: Nov 2024Est. completion: Nov 2030120 patients
N/ARecruiting
NCT03087136TevaLI

A Multicenter Observational Study to Evaluate Pediatric Multiple Sclerosis in Brazil

Start: Mar 2017Est. completion: Mar 2025100 patients
N/AUnknown
NCT02867917TevaLI

Comparison of Taste and Palatability in Fiber Supplements

Start: Nov 2016Est. completion: Dec 2016100 patients
N/ACompleted
NCT02893241TevaLI

Cafedrin/Theodrenalin (Akrinor®) Versus Ephedrine for Treatment of Hypotension in the Peri-operative Phase in Inpatient Setting

Start: Apr 2016Est. completion: Dec 20172,013 patients
N/ACompleted
NCT02938858TevaLI

French Registry of First-line Treatment of Acute Promyelocytic Leukemia

Start: Oct 2015Est. completion: Jul 2026400 patients
N/AActive Not Recruiting
NCT02515643TevaLI

Contribution of Renal Function to Endothelial Dysfunction in Living Kidney Donors and Transplant Recipients

Start: Jul 2015Est. completion: Dec 2017120 patients
N/AUnknown
NCT02140541TevaLI

The Clinical Profile of UK Asthma Patients With Raised Blood Eosinophils

Start: Feb 2013Est. completion: Jul 2014130,248 patients
N/AUnknown
NCT01865357TevaLI

Prospective Longitudinal 1-year Study of the Correlation Between Cognitive Functioning in Patients With Clinically Isolated Syndrome Suggestive of Multiple Sclerosis and Disconnection in the Brain Assessed by MRI

Start: Aug 2012Est. completion: Dec 2016117 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
11m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
11m ago

Office Administrator

SystImmune
11m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
22m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
25m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
25m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 138,486 patients
3 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)